The prognosis of mid‐range ejection fraction heart failure: a systematic review and meta‐analysis

AIMS: Mid‐range ejection fraction is a new entity of heart failure (HF) with undetermined prognosis till now. In our systematic review and meta‐analysis, we assess the mortality and hospitalization rates in mid‐range ejection fraction HF (HFmrEF) and compare them with those of reduced ejection fraction heart failure (HFrEF) and preserved ejection fraction HF (HFpEF). METHODS AND RESULTS: We conducted our search in March 2018 in the following databases for relevant articles: PubMed, CENTRAL, Google Scholar, Web of Science, Scopus, NYAM, SIEGLE, GHL, VHL, and POPLINE. Our primary endpoint was assessing all‐cause mortality and all‐cause hospital re‐admission rates in HFmrEF in comparison with HFrEF and HFpEF. Secondary endpoints were the possible causes of death and hospital re‐admission. Twenty‐five articles were included in our meta‐analysis with a total of 606 762 adult cardiac patients. Our meta‐analysis showed that HFmrEF had a lower rate of all‐cause death than had HFrEF [relative risk (RR), 0.9; 95% confidence interval (CI), 0.85–0.94]. HFpEF showed a higher rate of cardiac mortality than did HFmrEF (RR, 1.09; 95% CI, 1.02–1.16). Also, HFrEF had a higher rate of non‐cardiac mortality than had HFmrEF (RR, 1.31; 95% CI, 1.22–1.41). CONCLUSIONS: We detected a significant difference between HFrEF and HFmrEF regarding all‐cause death, and non‐cardiac death, while HFpEF differed significantly from HFmrEF regarding cardiac death.